The chemokine receptor subtype-4 (CXCR4) is an interesting new target for TRT, as it is overexpressed in more than 70% of human solid tumours, including breast, prostate, and cervical cancers and B-cell lymphoma, neuroblastoma, melanoma and gliomas. Here, CXCR4 is linked to cervical carcinoma.